The company recently received FDA 510(k) clearance and CE mark for the technology powered by a deep learning algorithm. It plans to roll out the AI-driven solution, designed to improve the quality of cone-beam computed tomography (CBCT) images, in the U.S. and Europe for use on the Allia platform.

CleaRecon DL brings AI-based 3D reconstruction to the interventional suite. It utilizes AI-based reconstruction to improve image quality by removing streaks without introducing additional artifacts. The company says it also designed the solution to improve CBCT analysis through clear images. According to GE HealthCare, it offers benefits in liver, prostate, neuro and endovascular aortic repair procedures.